IMPAX LABS (NASDAQ:IPXL)
11.54
+0.24 (2.12%)
| IMPAX LABS (NASDAQ:IPXL) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $11.30 | 52 Week High | $11.57 | ||
| Open | $11.41 | 52 Week Low | $2.50 | ||
| Day High | $11.64 | P/E | N/A | ||
| Day Low | $11.41 | EPS | $0.00 | ||
| Volume | 31,017 | ||||
| More IPXL Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| GLPC | 3 | AN | 1 |
| ABC | 1 | CBL | 1 |
| EXAS | 1 | ISTA | 1 |
| MXGL | 1 | PNX | 1 |
| SYMM | 1 | ETN | 1 |
| AMT | 1 | CRVL | 1 |
Entities who have mentioned IPXL
- Dividend | View Related Stories »
- JPMorgan | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Treasury Capital Purchase Program | View Related Stories »
- Goldman Sachs | View Related Stories »
- JMP Securities | View Related Stories »
- Citi | View Related Stories »
- UBS | View Related Stories »
- Factory Orders | View Related Stories »
- Trading Radar | View Related Stories »
- Wachovia | View Related Stories »
- Credit Suisse | View Related Stories »
- Deutsche Bank | View Related Stories »
- Morgan Stanley | View Related Stories »
- Banc of America | View Related Stories »
StreetInsider.com Major News for IPXL
View All ReportsStreetInsider.com Reports on IPXL
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Impax Laboratories (IPXL) Initiates Challenges to Abbott's Patents in Connection to TRICOR
- Impax Laboratories (IPXL) Initiates Phase III Trial of IPX066 in Parkinson's
- Impax Laboratories (IPXL) Settles FLOMAX Litigation
- Impax Laboratories (IPXL) Announces Tentative FDA Approval For Generic FLOMAX
View All Press ReleasesCompany Press Releases on IPXL
- Impax Laboratories Drives Stronger Performance with IBM Business Analytics
- Impax Laboratories to Present at the Credit Suisse 18th Annual Healthcare Conference
- Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets
- Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson's Disease
StreetInsider Reports on IPXL by Category
View All BlogsBlogs on IPXL
- Developments for Parkinson's Disease Ignite Investor Enthusiasm
- Analyst upgrades, downgrades and initiations: AXP, CL, DLTR, PG, RIMM, UAUA ...
- Biotech News Bytes: Neuralstem, Questcor, Valeant, Impax
- Update on Pequot Capital's Portfolio Unwind
- Treating Parkinson’s Disease - Investment Opportunities and Challenges
View All FilingsSEC Filings on IPXL
- Form 4 IMPAX LABORATORIES INC For: Nov 06 Filed by: MARKBREITER MICHAEL
- Form 10-Q IMPAX LABORATORIES INC For: Sep 30
- Form 8-K IMPAX LABORATORIES INC For: Nov 03
Comments on recent IPXL articles
Comments on IPXL
No comments are currently available.
on Nov 13, 2009
at 03:55 PM ANDREW OLIVER SATCHELL EXCELLENT
Article: Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
on Dec 10, 2008
at 05:17 AM casual male casual male needs to be taken over it does not know how to price effectively to draw in clients. It makes the larger man pay more for clothing just because they are man of larger size. Being in retail for many years I have never seen a company not run instore promotions during this difficult economic times. Being employed there I see the need for a takeover and get rid of currrent regional and district managment because they find it so easy to work from home and hardly ever visiting there stores unless there is a crisis in the building.
Article: SAC Capital discloses 6.2% stake in Casual Male (CMRG), 5% in Impax Laboratories (IPXL)